A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled “Leukopenia, weight loss and oral ...

Patients with tumors that did not express thymidylate synthase responded to chemotherapy. Inhibition of thymidylate synthase is one of the main mechanisms of action of 5-FU and previous findings ...

A new research paper was published in Oncotarget , Volume 16, on February 18, 2025, titled "Leukopenia, weight loss and oral ...

A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...

Oral mucositis affects many cancer patients undergoing 5-Fluorouracil (5-FU) chemotherapy, often leading to difficulty in eating, drinking, and speaking. Despite its prevalence, effective ...

Third, the external validity of this trial is low, owing to selection of patients: those progressing after 5-FU, but still eligible for aggressive chemotherapy were included. The IROX results ...

To our knowledge, this is the first-in-animal preliminary study, which used a biocompatible electrospun membrane with the addition of autologous ...

Patients with metastatic or unresectable gastric cancer are usually given 5-fluorouracil (5-FU) and platinum-based chemotherapy, but patients with advance disease usually have a poor prognosis. The ...

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.

Silexion Therapeutics Corp. has released new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA candidate, SIL-204, in combination with components of ...